Showing results (321-330 of 341) with videos related to
Sort By:
Pageof 35
Blood|January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 24, 2020
Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated DonorsJack W Hsu, Bronwen E Shaw, Soyoung Kim, et al.Blood Advances|July 30, 2026
Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.Blood Advances|February 25, 2020
Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yieldNosha Farhadfar, Jack W Hsu, Brent R Logan, et al.Blood Advances|June 19, 2019
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patientsLeylah M Drusbosky, Neeraj Kumar Singh, Kimberly E Hawkins, et al.Blood Advances|July 1, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemiaMark J Levis, Mehdi Hamadani, Brent R Logan, et al.The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.Bone Marrow Transplantation|May 2, 2020
Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysisNosha Farhadfar, Hemant S Murthy, Brent R Logan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3Mark J Levis, Mehdi Hamadani, Brent Logan, et al.Blood Advances|May 13, 2020
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseasesJustine M Kahn, Ruta Brazauskas, Heather R Tecca, et al.Pageof 35